Possible impact of phthalates on infant reproductive health

G Lottrup1, A-M Andersson, H Leffers

  • 1University Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark.

Insights

Perinatal exposure to phthalates may harm infant male reproductive development. Studies link phthalate exposure to altered hormone levels and reduced anogenital index in boys, suggesting potential anti-androgenic effects.

Area of Science:

  • Reproductive Toxicology
  • Environmental Health
  • Pediatric Endocrinology

Background:

  • Phthalates are industrial chemicals with known adverse effects on the male reproductive system in animal models, particularly following in utero exposure.
  • Limited data exists on the human health effects of phthalates, especially concerning perinatal exposure and its impact on male infants.
  • Animal studies indicate severe reproductive system disruption from phthalates, but human susceptibility and specific effects remain less understood.

Purpose of the Study:

  • To investigate the potential adverse effects of perinatal phthalate exposure on human male reproductive development.
  • To examine the association between phthalate metabolites in breast milk and maternal urine with reproductive hormone levels and genital development in infant boys.
  • To assess the potential anti-androgenic effects of phthalates in human infants.

Main Methods:

  • Analysis of phthalate monoesters in breast milk samples and correlation with reproductive hormone levels (testosterone, SHBG, LH) in healthy infant boys.
  • Measurement of phthalate metabolites in maternal urine samples collected during late pregnancy and correlation with the anogenital index (AGI) in infant boys.
  • Comparison of findings with established animal toxicology data on phthalate exposure.

Main Results:

  • Five phthalates (MEP, MBP, MMP, MEHP, MiNP) correlated with altered hormone levels in infant boys, indicating reduced androgen activity and Leydig cell function.
  • Elevated levels of MEP and MBP were associated with increased sex hormone-binding globulin (SHBG) and LH/testosterone ratios.
  • Increased maternal urinary levels of MBP, MEP, monobenzyl-, and mono-isobutyl phthalate were linked to a reduced anogenital index (AGI) in infant boys, associated with cryptorchidism and smaller genital size.

Conclusions:

  • Perinatal phthalate exposure is associated with anti-androgenic effects in human infants, mirroring some animal study findings.
  • Specific phthalates like MEP may have effects predominantly observed in humans, possibly due to unique exposure routes or metabolism.
  • These findings raise significant concerns regarding the safety of phthalate exposure for pregnant women and infants due to widespread production and use.

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
Types of Toxins01:36

Types of Toxins

Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...